EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Long‐Term Safety and Efficacy of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE / ADHERE + Trial Interim Analysis

Jeffrey A Allen iD, Geoffrey Istas, Satoshi Kuwabara iD, Trevor Mole, Luis Querol iD, Simon Rinaldi, Mark Stettner, Benjamin Van Hoorick, Richard A Lewis

Journal of the Peripheral Nervous System · 2026-09 · 31 (3)

DOI: 10.1111/jns.70140 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the Peripheral Nervous System, online erschienen am 16.07.2026. Verfasst von Jeffrey A Allen und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Outcome Assessment, Health Care, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: argenx.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims In ADHERE, subcutaneous efgartigimod PH20 (1000 mg once weekly) was effective and well tolerated in participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). ADHERE+ is an open‐label extension of ADHERE assessing long‐term safety and efficacy.

Methods

Eligible participants from ADHERE run‐in period (prior CIDP treatments discontinued), stage A (open‐label efgartigimod), and stage B (stage A responders randomized to placebo or efgartigimod) could roll over to ADHERE+ and receive efgartigimod. The primary outcome was to assess long‐term safety and tolerability. Efficacy outcomes evaluated adjusted Inflammatory Neuropathy Cause and Treatment (aINCAT) score, Inflammatory Rasch‐built Overall Disability Scale (I‐RODS) score, and mean grip strength (GS) from ADHERE run‐in baseline through ADHERE+ week 36.

Results

At interim data cut‐off (February 16, 2024), 228/229 eligible participants advanced to ADHERE+. Prolonged efgartigimod exposure did not increase the incidence ( n = 171/228 [75.0%]) or severity of TEAEs (grade ≥ 3 TEAEs, n = 41/228 [18.0%]); regardless of immunoglobulin G level, there was a low incidence of infections. Stage A responders reported long‐term clinically meaningful improvements in mean aINCAT (decreased by 1.2 points), I‐RODS centile metric (increase of 8.8 points), and GS scores (increase of 17.5 kPa) from run‐in baseline to ADHERE+ week 36, irrespective of stage B treatment.

Interpretation

Interim results from ADHERE+ indicate long‐term efgartigimod PH20 treatment in participants with CIDP was well tolerated (maximum exposure = 187.3 weeks; mean (SD) treatment duration = 58.0 [33.8] weeks). Clinically meaningful improvements in disability and strength were observed across assessments, regardless of stage B treatment or prior treatment status, with greater improvements seen over time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Outcome Assessment, Health CarePolyradiculoneuropathy, Chronic Inflammatory DemyelinatingAntibodies, Monoclonal, HumanizedAdultAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

FcRnINCATI‐RODSchronic inflammatory demyelinating polyradiculoneuropathyefgartigimod

Substanzen

efgartigimod alfaAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • University of Minnesota, Minneapolis, Minnesota, USA.
  • argenx, Ghent, Belgium.
  • Chiba University, Chiba, Japan.
  • Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Centro De Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Madrid, Spain.
  • University of Oxford, Oxford, UK.

ORCID-Profile: Jeffrey A Allen, Satoshi Kuwabara, Luis Querol

Förderung

  • argenx

Zitieren

APA

Allen, J. A., Istas, G., Kuwabara, S., Mole, T., Querol, L., Rinaldi, S., Stettner, M., Van Hoorick, B., & Lewis, R. A. (2026). Long‐Term Safety and Efficacy of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE / ADHERE + Trial Interim Analysis. Journal of the Peripheral Nervous System, 31(3). https://doi.org/10.1111/jns.70140

Vancouver

Allen JA, Istas G, Kuwabara S, Mole T, Querol L, Rinaldi S, et al. Long‐Term Safety and Efficacy of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE / ADHERE + Trial Interim Analysis. Journal of the Peripheral Nervous System. 2026;31(3). doi:10.1111/jns.70140

BibTeX
@article{Allen2026,
  author = {Allen, Jeffrey A and Istas, Geoffrey and Kuwabara, Satoshi and Mole, Trevor and Querol, Luis and Rinaldi, Simon and Stettner, Mark and Van Hoorick, Benjamin and Lewis, Richard A},
  title = {Long‐Term Safety and Efficacy of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE / ADHERE + Trial Interim Analysis},
  journal = {Journal of the Peripheral Nervous System},
  year = {2026},
  volume = {31},
  number = {3},
  doi = {10.1111/jns.70140}
}
Kostenlos starten →